Securing the Top Spot for Nine Consecutive Months in the Generic Market Since its April Launch for Dapagliflozin
Boryung, a leading pharmaceutical company, announced on January 24th that its diabetes treatment drug 'Trudapa' secured the top spot in the generic market for 'Dapagliflozin.' According to a survey conducted by the pharmaceutical market research firm UBIST, Trudapa generated $3.1 million in prescription sales revenue in 2023. This accounts for approximately 14% of the total generic market size for both Dapagliflozin single and Dapagliflozin-Metformin combination, which stands at $22.1 million.
Notably, Trudapa has maintained its position as the leading player in the Dapagliflozin generic market for nine consecutive months since its launch in April 2023, as highlighted by Boryung.
In addition to expanding the market share of the Trudapa product line, Boryung is strategically planning to strengthen its dominance in the diabetes field through a diverse portfolio of self-developed products. The company began this initiative with the launch of the 'Trusita' product line in September 2023, featuring single and combination formulations with the Sitagliptin component. In November 2023, Boryung introduced 'Trubuddy,' the world's first combination diabetes medication, which combines the SGLT-2 inhibitor 'Dapagliflozin' with the TZD (Thiazolidinedione) class medication Pioglitazone.
Looking ahead, Boryung aims to further expand its portfolio of diabetes treatment drugs, including the upcoming launch of 'Linagliptin' single and combination formulations this year. The company has expressed its commitment to ongoing efforts in developing combination medications that address both diabetes and hypertension, extending indications to include comorbid conditions.
Baek-Min Sung, Head of Rx Marketing at Boryung, emphasized the company's focus on introducing essential products for diabetes treatment and establishing clinical evidence. He stated, "In the future, Boryung will continue to introduce a variety of combinations of diabetes medications, while strengthening academic, sales, and marketing activities to play a central role in diabetes treatment."